202 related articles for article (PubMed ID: 19101156)
1. Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
Feng Z; Hellberg MR; Sharif NA; McLaughlin MA; Williams GW; Scott D; Wallace T
Bioorg Med Chem; 2009 Jan; 17(2):576-84. PubMed ID: 19101156
[TBL] [Abstract][Full Text] [Related]
2. Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists.
Bhattacherjee P; Williams BS; Paterson CA
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):3047-53. PubMed ID: 10549672
[TBL] [Abstract][Full Text] [Related]
3. AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey.
Selliah RD; Hellberg MR; Sharif NA; McLaughlin MA; Williams GW; Scott DA; Earnest D; Haggard KS; Dean WD; Delgado P; Gaines MS; Conrow RE; Klimko PG
Bioorg Med Chem Lett; 2004 Sep; 14(17):4525-8. PubMed ID: 15357985
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog.
Sharif NA; McLaughlin MA; Kelly CR; Xu S; Crider JY; Williams GW; Parker JL
J Ocul Pharmacol Ther; 2006 Oct; 22(5):291-309. PubMed ID: 17076623
[TBL] [Abstract][Full Text] [Related]
5. 15-Fluoro prostaglandin FP agonists: a new class of topical ocular hypotensives.
Klimko P; Hellberg M; McLaughlin M; Sharif N; Severns B; Williams G; Haggard K; Liao J
Bioorg Med Chem; 2004 Jul; 12(13):3451-69. PubMed ID: 15186831
[TBL] [Abstract][Full Text] [Related]
6. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
Stjernschantz J; Selén G; Astin M; Resul B
Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
[TBL] [Abstract][Full Text] [Related]
7. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.
Sharif NA; Kelly CR; Crider JY; Williams GW; Xu SX
J Ocul Pharmacol Ther; 2003 Dec; 19(6):501-15. PubMed ID: 14733708
[TBL] [Abstract][Full Text] [Related]
8. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management.
Bito LZ; Stjernschantz J; Resul B; Miranda OC; Basu S
J Lipid Mediat; 1993; 6(1-3):535-43. PubMed ID: 8358014
[TBL] [Abstract][Full Text] [Related]
9. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
[TBL] [Abstract][Full Text] [Related]
10. Effects of prostaglandin F2alpha and latanoprost on phosphoinositide turnover, myosin light chain phosphorylation and contraction in cat iris sphincter.
Ansari HR; Davis AM; Kaddour-Djebbar I; Abdel-Latif AA
J Ocul Pharmacol Ther; 2003 Jun; 19(3):217-31. PubMed ID: 12828840
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).
Woodward DF; Krauss AH; Chen J; Liang Y; Li C; Protzman CE; Bogardus A; Chen R; Kedzie KM; Krauss HA; Gil DW; Kharlamb A; Wheeler LA; Babusis D; Welty D; Tang-Liu DD; Cherukury M; Andrews SW; Burk RM; Garst ME
J Pharmacol Exp Ther; 2003 May; 305(2):772-85. PubMed ID: 12606640
[TBL] [Abstract][Full Text] [Related]
12. 3-Oxa-15-cyclohexyl prostaglandin DP receptor agonists as topical antiglaucoma agents.
Hellberg MR; Conrow RE; Sharif NA; McLaughlin MA; Bishop JE; Crider JY; Dean WD; DeWolf KA; Pierce DR; Sallee VL; Selliah RD; Severns BS; Sproull SJ; Williams GW; Zinke PW; Klimko PG
Bioorg Med Chem; 2002 Jun; 10(6):2031-49. PubMed ID: 11937363
[TBL] [Abstract][Full Text] [Related]
13. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M; Nair S; Rui E; Lafontaine J; Almaden CD; Wells P; Krauss A
Exp Eye Res; 2009 Nov; 89(5):608-17. PubMed ID: 19445930
[TBL] [Abstract][Full Text] [Related]
14. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes.
Bito LZ; Draga A; Blanco J; Camras CB
Invest Ophthalmol Vis Sci; 1983 Mar; 24(3):312-9. PubMed ID: 6572617
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist.
Hellberg MR; Sallee VL; McLaughlin MA; Sharif NA; Desantis L; Dean TR; Zinke PW
J Ocul Pharmacol Ther; 2001 Oct; 17(5):421-32. PubMed ID: 11765147
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment.
Stjernschantz J
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():63-8. PubMed ID: 7732906
[No Abstract] [Full Text] [Related]
17. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans.
Camras CB
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():519-25. PubMed ID: 7732900
[No Abstract] [Full Text] [Related]
18. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents.
Nakajima T; Matsugi T; Goto W; Kageyama M; Mori N; Matsumura Y; Hara H
Biol Pharm Bull; 2003 Dec; 26(12):1691-5. PubMed ID: 14646172
[TBL] [Abstract][Full Text] [Related]
19. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences.
Bean GW; Camras CB
Surv Ophthalmol; 2008 Nov; 53 Suppl1():S69-84. PubMed ID: 19038626
[TBL] [Abstract][Full Text] [Related]
20. Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment.
Stjernschantz J
Exp Eye Res; 2004 Apr; 78(4):759-66. PubMed ID: 15037110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
